Market Overview:
The global medication treatment of metastatic bone disease market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer, rising geriatric population, and technological advancements in the field of medication treatment for metastatic bone disease. The global medication treatment of metastatic bone disease market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into chemotherapy, hormone therapy, bisphosphonates, opiate therapy Immunotherapy).
Product Definition:
Medication Treatment of Metastatic Bone Disease is the use of medication to treat metastatic bone disease. The importance of Medication Treatment of Metastatic Bone Disease is that it can help to reduce or prevent pain, improve function, and extend life.
Chemotherapy:
Chemotherapy is a group of medical drugs or therapy used to treat cancer. The major goal of chemotherapy is to kill all the cancer cells, so that they cannot reproduce and grow into an abnormal new cell. There are many different types of chemotherapies such as anthracycline, alkylating agents, cytotoxic agents (chemotherapy), plant derivatives (vincristine), and hormonal therapies.
Hormone Therapy:
Hormone therapy is used in the treatment of metastatic bone disease. It includes hormone replacement therapy and hormone antagonists. Hormone replacement therapies include estrogen and testosterone Replacement Therapy (RT). Testosterone has been widely used as an anti-androgen in women with prostate cancer to treat symptoms of gynecomastia, but it is now known to have adverse effects on patients with a history of breast cancer.
Application Insights:
The others application segment held the largest share of revenue in 2017. This is due to the increasing incidence of metastatic bone disease and other associated conditions, such as osteoporosis and fractures. According to a study published by NCBI in 2018, around 1% of people above 60 years have hip fractures every year. The risk increases with age and for people above 80 years it approaches 5%. Thus, increasing geriatric population is one of the major drivers for this segment.
Hospitals were estimated as largest application segment owing to growing awareness about early diagnosis & treatment along with availability of advanced healthcare facilities & services across various regions worldwide. As per WHO estimates, around 50% or more patients are diagnosed at hospitals than clinics or primary care centers due to better diagnostic capabilities at these institutions coupled with availability of highly skilled medical staffs who can conduct accurate diagnostics quickly resulting in faster treatment procedures which further boosts market growth during hospitalization period.
Regional Analysis:
North America dominated the global medication treatment of metastatic bone disease market with a share of 42.0% in 2017. This is due to the presence of well-established healthcare facilities, availability of highly skilled physicians, and high patient awareness levels coupled with relatively higher healthcare expenditure levels in this region as compared to other regions. Moreover, increasing government initiatives for funding research activities pertaining to rare diseases are also expected to drive growth over the forecast period.
Growth Factors:
- Increasing incidence of metastatic bone disease
- Growing awareness about the availability and benefits of medication treatment for metastatic bone disease
- Rising demand for better quality of life among patients with metastatic bone disease
- Technological advancements in medication treatment for metastatic bone disease
- Increasing focus on research and development activities to develop novel medications for the treatment of metastatic bone disease
Scope Of The Report
Report Attributes
Report Details
Report Title
Medication Treatment of Metastatic Bone Disease Market Research Report
By Type
Chemotherapy, Hormone Therapy, Bisphosphonates, Opiate Therapy, Immunotherapy
By Application
Hospitals, Clinics, Others
By Companies
Amgen, Merck & Co, Roche, Novartis, Eli Lilly and Company, Bayer, Fresenius Kabi, BTG plc, Boston Scientific, Medtronic
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
211
Number of Tables & Figures
148
Customization Available
Yes, the report can be customized as per your need.
Global Medication Treatment of Metastatic Bone Disease Market Report Segments:
The global Medication Treatment of Metastatic Bone Disease market is segmented on the basis of:
Types
Chemotherapy, Hormone Therapy, Bisphosphonates, Opiate Therapy, Immunotherapy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Amgen
- Merck & Co
- Roche
- Novartis
- Eli Lilly and Company
- Bayer
- Fresenius Kabi
- BTG plc
- Boston Scientific
- Medtronic
Highlights of The Medication Treatment of Metastatic Bone Disease Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Chemotherapy
- Hormone Therapy
- Bisphosphonates
- Opiate Therapy
- Immunotherapy
- By Application:
- Hospitals
- Clinics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Medication Treatment of Metastatic Bone Disease Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
There is no one-size-fits-all answer to this question, as the best medication treatment for metastatic bone disease will vary depending on the individual's specific situation and medical history. However, some common types of medication used to treat metastatic bone disease include chemotherapy drugs such as doxorubicin or vincristine, targeted therapy drugs such as pembrolizumab (Keytruda), and monoclonal antibodies such as rituximab (Rituxan).
Some of the key players operating in the medication treatment of metastatic bone disease market are Amgen, Merck & Co, Roche, Novartis, Eli Lilly and Company, Bayer, Fresenius Kabi, BTG plc, Boston Scientific, Medtronic.
The medication treatment of metastatic bone disease market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Medication Treatment of Metastatic Bone Disease Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Medication Treatment of Metastatic Bone Disease Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Medication Treatment of Metastatic Bone Disease Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Medication Treatment of Metastatic Bone Disease Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Medication Treatment of Metastatic Bone Disease Market Size & Forecast, 2018-2028
4.5.1 Medication Treatment of Metastatic Bone Disease Market Size and Y-o-Y Growth
4.5.2 Medication Treatment of Metastatic Bone Disease Market Absolute $ Opportunity
Chapter 5 Global Medication Treatment of Metastatic Bone Disease Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Medication Treatment of Metastatic Bone Disease Market Size Forecast by Type
5.2.1 Chemotherapy
5.2.2 Hormone Therapy
5.2.3 Bisphosphonates
5.2.4 Opiate Therapy
5.2.5 Immunotherapy
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Medication Treatment of Metastatic Bone Disease Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Medication Treatment of Metastatic Bone Disease Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Medication Treatment of Metastatic Bone Disease Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Medication Treatment of Metastatic Bone Disease Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Medication Treatment of Metastatic Bone Disease Analysis and Forecast
9.1 Introduction
9.2 North America Medication Treatment of Metastatic Bone Disease Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Medication Treatment of Metastatic Bone Disease Market Size Forecast by Type
9.6.1 Chemotherapy
9.6.2 Hormone Therapy
9.6.3 Bisphosphonates
9.6.4 Opiate Therapy
9.6.5 Immunotherapy
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Medication Treatment of Metastatic Bone Disease Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Medication Treatment of Metastatic Bone Disease Analysis and Forecast
10.1 Introduction
10.2 Europe Medication Treatment of Metastatic Bone Disease Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Medication Treatment of Metastatic Bone Disease Market Size Forecast by Type
10.6.1 Chemotherapy
10.6.2 Hormone Therapy
10.6.3 Bisphosphonates
10.6.4 Opiate Therapy
10.6.5 Immunotherapy
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Medication Treatment of Metastatic Bone Disease Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Medication Treatment of Metastatic Bone Disease Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Medication Treatment of Metastatic Bone Disease Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Medication Treatment of Metastatic Bone Disease Market Size Forecast by Type
11.6.1 Chemotherapy
11.6.2 Hormone Therapy
11.6.3 Bisphosphonates
11.6.4 Opiate Therapy
11.6.5 Immunotherapy
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Medication Treatment of Metastatic Bone Disease Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Medication Treatment of Metastatic Bone Disease Analysis and Forecast
12.1 Introduction
12.2 Latin America Medication Treatment of Metastatic Bone Disease Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Medication Treatment of Metastatic Bone Disease Market Size Forecast by Type
12.6.1 Chemotherapy
12.6.2 Hormone Therapy
12.6.3 Bisphosphonates
12.6.4 Opiate Therapy
12.6.5 Immunotherapy
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Medication Treatment of Metastatic Bone Disease Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Medication Treatment of Metastatic Bone Disease Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Medication Treatment of Metastatic Bone Disease Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Medication Treatment of Metastatic Bone Disease Market Size Forecast by Type
13.6.1 Chemotherapy
13.6.2 Hormone Therapy
13.6.3 Bisphosphonates
13.6.4 Opiate Therapy
13.6.5 Immunotherapy
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Medication Treatment of Metastatic Bone Disease Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Medication Treatment of Metastatic Bone Disease Market: Competitive Dashboard
14.2 Global Medication Treatment of Metastatic Bone Disease Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Amgen
14.3.2 Merck & Co
14.3.3 Roche
14.3.4 Novartis
14.3.5 Eli Lilly and Company
14.3.6 Bayer
14.3.7 Fresenius Kabi
14.3.8 BTG plc
14.3.9 Boston Scientific
14.3.10 Medtronic
